Acorda completes Neuronex acquisition as diazepam nasal spray nears NDA

Acorda Therapeutics paid $6.8 million on 20 December to complete the acquisition of Neuronex and the Ardsley, New York-based company will make up to $134 million in additional milestone payments plus royalties for Neuronex's patient-friendly intranasal formulation of diazepam for the control of acute repetitive seizures (ARS).

Acorda Therapeutics paid $6.8 million on 20 December to complete the acquisition of Neuronex and the Ardsley, New York-based company will make up to $134 million in additional milestone payments plus royalties for Neuronex's patient-friendly intranasal formulation of diazepam for the control of acute repetitive seizures (ARS).

Acorda paid $2 million upfront in early 2012 and invested about $1.5 million in research and development in exchange for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category